Picture Berlin Partner Hotspot for Startups 650x80px
Document › Details

Charles River Laboratories International, Inc.. (1/16/20). "Press Release: Charles River Laboratories and Fios Genomics Form a Strategic Alliance to Provide Bioinformatics-driven Drug Discovery and Safety Assessment". Wilmington, MA & Edinburgh.

Organisations Organisation Charles River Laboratories International Inc. (NYSE: CRL)
  Group Charles River (Group)
  Organisation 2 Fios Genomics Ltd.
Products Product software tools (bioinformatics)
  Product 2 drug discovery
Index term Index term Charles River–Fios Genomics: bioinformatics, 202001– collab providing Charles River’s customers access to Fios data analysis services
Persons Person Girshik, Birgit (Charles River 201703 SVP Global Discovery)
  Person 2 Lynagh, Sarah (Fios Genomics 202001 CEO)

Together, Charles River and Fios Genomics aim to accelerate preclinical discovery and development by turning complex data into actionable information

Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has entered into an exclusive partnership with Fios Genomics, a leading provider of bioinformatics data analysis services.

Access to high quality, transparent bioinformatics presents a challenge for many drug development teams. Compiling disparate, complex data file types into single datasets for interpretation requires a rigorous assessment of data quality, as well as an analytical approach that emphasizes biological relevance and the assessment of statistical significance.

Through this partnership, Charles River clients will have access to Fios Genomics’ expertise in bioinformatics, statistics and biology to assist in the sourcing and analysis of the high-dimensional, multi-variant datasets associated with drug development including microarrays, next-generation sequencing (NGS), proteomics, metabolomics and epigenetics as well as the associated meta-data.

The biologically-relevant insights revealed by the team at Fios Genomics, combined with Charles River’s streamlined integrated drug discovery and development platform and the scientific expertise of both organizations, will enable Charles River clients to make more data-driven decisions about their programs, improving both confidence and speed.

Approved Quotes

“The explosion in -omics data has been a boon for the drug discovery industry, but analysis and interpretation of these datasets are challenging. Through our partnership with Fios Genomics, Charles River clients will have greater access to the special combination of skills in bioinformatics, statistics and biology required to obtain meaningful information from their data.” –Birgit Girshick, Corporate Executive Vice President, Discovery & Safety Assessment, Biologics Testing Solutions, and Avian Vaccine Services at Charles River

“Our approach to bioinformatics at Fios Genomics is to look beyond algorithms and statistics and understand that biological relevance and statistical significance are not necessarily the same thing. Bioinformatics is about biology, outcome and pathways, and by partnering with Charles River, we can help more researchers make data-driven decisions about their programs that are grounded in biological insights.” –Sarah Lynagh, PhD, Chief Executive Officer at Fios Genomics

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit

About Fios Genomics

Fios Genomics provide a wide range of bioinformatics analysis services, supporting drug discovery and development and applied research across all species. Using the best in class tools and methods, Fios provide a functional and interactive reporting architecture, allowing scientists to fully explore their data. We can analyse ‘omics data in combination with other outputs from experiments or trials such as imaging data and clinical information. This helps to build up the data picture while ensuring that a robust analysis is delivered. To learn more about our capabilities, visit

Investor Contact:
Todd Spencer
Corporate Vice President, Investor Relations

Media Contact:
Charles River
Amy Cianciaruso
Corporate Vice President, Public Relations

Fios Genomics
Callum Spreng
Managing Director, Spreng Thomson
+44 (0)141 548 5191

Record changed: 2020-02-29


Picture [iito] Plain Stupid Simple 650x80px

More documents for Charles River (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture [iito] Back into Ad 650x80px

» top